A new clinical trial has demonstrated that CAR T-cell therapy can substantially decrease disease activity in patients suffering from particularly severe rheumatoid arthritis, according to research published in the journal Nature Medicine and reported by News Medical. The findings mark the results of the world’s first clinical trial of its kind, offering a potential path forward for individuals with treatment-resistant autoimmune conditions.
The initial phase of the COMPARE trial evaluated six patients at Charité – Universitätsmedizin Berlin. The participant group comprised three women and three men aged 31 to 69 years. Over the preceding decade, these patients had received up to eight targeted or biologic therapies without achieving sufficient effectiveness. Researchers sought to determine whether CAR T-cells could safely track down and eliminate disease-driving cells in the joints.
Targeting Disease-Driving B Cells Through CD19 Receptors
Immunotherapies such as CAR T-cell therapy have historically been utilized primarily to treat cancer. While cancer treatments train immune cells to recognize and eliminate tumor cells, the application for autoimmune diseases is designed to target abnormal memory cells that fuel chronic inflammation.
Prof. David Simon, who designed the trial for this patient group, explained that disease-driving B cells—memory cells of the adaptive immune system—can survive in lymph nodes, bone marrow, or joint tissue following an infection. These cells produce harmful antibodies directed against the body’s own tissues and repeatedly reignite inflammation. The identifying surface molecule found on both abnormal B cells in blood and lymphatic cancers and disease-driving B cells in rheumatoid arthritis is CD19, which functions as a molecular name tag.
To prepare the treatment, T cells are collected from the patient’s blood in a laboratory setting. These cells are genetically modified and equipped with a chimeric antigen receptor, or CAR, which acts as a search sensor that binds specifically to the CD19 molecule. Before the modified immune cells are returned via a single infusion, patients undergo a short course of preparatory chemotherapy to temporarily reduce certain immune cells, allowing the CAR T cells to multiply effectively.
Promising Results and the Path Forward for Autoimmune Research
Once inside the body, the modified immune cells target cells carrying the CD19 marker, temporarily eliminating all CD19-positive B cells. This process enables the immune system to reset and helps eliminate long-lived, disease-driving B cells residing in hard-to-reach joint tissues. The safety and efficacy results from the initial part of the trial showed that disease activity decreased markedly across all six study participants.
The successful trial adds to a growing body of scientific inquiry exploring how patient-specific immunotherapies manufactured from an individual’s own immune cells could eventually help manage or cure autoimmune diseases. As researchers continue to analyze the data from these early trials, the approach highlights a shift in strategy from merely managing chronic symptoms to resetting aberrant immune responses in difficult-to-treat patient populations.
Читайте также
